{"filing":{"accession_number":"0001213900-26-098792","cik":"0001139685","ticker":"AIDX","company_name":"20/20 Biolabs, Inc.","form":"8-K","filing_date":"2026-09-10","report_date":"2026-09-03","primary_document":"ea0305119-8k_2020bio.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1139685/000121390026098792/ea0305119-8k_2020bio.htm"},"events":[{"id":32656,"run_id":30017,"accession_number":"0001213900-26-098792","anchor_item_number":"3.01","event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"summary":"The filing discloses two separate Nasdaq compliance failures: (1) failure to maintain the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), with a 180-calendar day compliance period ending January 13, 2027, and (2) failure to maintain the $2,500,000 stockholders' equity requirement under Listing Rule 5550(b)(1), with a 45-calendar day plan submission deadline. The Company explicitly states that if it does not regain compliance within the allotted periods, \"Nasdaq will provide notice that the Company's common stock will be subject to delisting.\" This is a direct delisting risk disclosure under Item 3.01.","company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","filing_date":"2026-09-10","form":"8-K","submitted_at":null,"items":[{"id":35883,"accession_number":"0001213900-26-098792","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"The filing discloses two separate Nasdaq compliance failures: (1) failure to maintain the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), with a 180-calendar day compliance period ending January 13, 2027, and (2) failure to maintain the $2,500,000 stockholders' equity requirement under Listing Rule 5550(b)(1), with a 45-calendar day plan submission deadline. The Company explicitly states that if it does not regain compliance within the allotted periods, \"Nasdaq will provide notice that the Company's common stock will be subject to delisting.\" This is a direct delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:13:03.614168+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":35883,"accession_number":"0001213900-26-098792","item_number":"3.01","item_title":null,"event_type":"delisting_risk","event_domain":"terminal","is_material":true,"confidence":0.98,"reasoning":"The filing discloses two separate Nasdaq compliance failures: (1) failure to maintain the $1.00 minimum bid price requirement under Listing Rule 5550(a)(2), with a 180-calendar day compliance period ending January 13, 2027, and (2) failure to maintain the $2,500,000 stockholders' equity requirement under Listing Rule 5550(b)(1), with a 45-calendar day plan submission deadline. The Company explicitly states that if it does not regain compliance within the allotted periods, \"Nasdaq will provide notice that the Company's common stock will be subject to delisting.\" This is a direct delisting risk disclosure under Item 3.01.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-10T20:13:03.614168+00:00","company_name":"20/20 Biolabs, Inc.","ticker":"AIDX","filing_date":"2026-09-10"}]}